# Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3

> **NCT01808248** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 47 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** SOF
- **DRUG:** PEG
- **DRUG:** RBV

## Key facts

- **NCT ID:** NCT01808248
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2013-09
- **Final completion:** 2013-12
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2014-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01808248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01808248, "Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01808248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*